Cargando…

Ongoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory Agents

In chronic human immunodeficiency virus (HIV)-1 infection, long-lived latently infected cells are the major barrier to virus eradication and functional cure. Several therapeutic strategies to perturb, eliminate, and/or control this reservoir are now being pursued in the clinic. These strategies incl...

Descripción completa

Detalles Bibliográficos
Autores principales: Delagrèverie, Héloïse M., Delaugerre, Constance, Lewin, Sharon R., Deeks, Steven G., Li, Jonathan Z.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5066458/
https://www.ncbi.nlm.nih.gov/pubmed/27757411
http://dx.doi.org/10.1093/ofid/ofw189
_version_ 1782460491602329600
author Delagrèverie, Héloïse M.
Delaugerre, Constance
Lewin, Sharon R.
Deeks, Steven G.
Li, Jonathan Z.
author_facet Delagrèverie, Héloïse M.
Delaugerre, Constance
Lewin, Sharon R.
Deeks, Steven G.
Li, Jonathan Z.
author_sort Delagrèverie, Héloïse M.
collection PubMed
description In chronic human immunodeficiency virus (HIV)-1 infection, long-lived latently infected cells are the major barrier to virus eradication and functional cure. Several therapeutic strategies to perturb, eliminate, and/or control this reservoir are now being pursued in the clinic. These strategies include latency reversal agents (LRAs) designed to reactivate HIV-1 ribonucleic acid transcription and virus production and a variety of immune-modifying drugs designed to reverse latency, block homeostatic proliferation, and replenish the viral reservoir, eliminate virus-producing cells, and/or control HIV replication after cessation of antiretroviral therapy. This review provides a summary of ongoing clinical trials of HIV LRAs and immunomodulatory molecules, and it highlights challenges in the comparison and interpretation of the expected trial results.
format Online
Article
Text
id pubmed-5066458
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-50664582016-10-18 Ongoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory Agents Delagrèverie, Héloïse M. Delaugerre, Constance Lewin, Sharon R. Deeks, Steven G. Li, Jonathan Z. Open Forum Infect Dis Review Articles In chronic human immunodeficiency virus (HIV)-1 infection, long-lived latently infected cells are the major barrier to virus eradication and functional cure. Several therapeutic strategies to perturb, eliminate, and/or control this reservoir are now being pursued in the clinic. These strategies include latency reversal agents (LRAs) designed to reactivate HIV-1 ribonucleic acid transcription and virus production and a variety of immune-modifying drugs designed to reverse latency, block homeostatic proliferation, and replenish the viral reservoir, eliminate virus-producing cells, and/or control HIV replication after cessation of antiretroviral therapy. This review provides a summary of ongoing clinical trials of HIV LRAs and immunomodulatory molecules, and it highlights challenges in the comparison and interpretation of the expected trial results. Oxford University Press 2016-10-07 /pmc/articles/PMC5066458/ /pubmed/27757411 http://dx.doi.org/10.1093/ofid/ofw189 Text en © The Author 2016. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com.
spellingShingle Review Articles
Delagrèverie, Héloïse M.
Delaugerre, Constance
Lewin, Sharon R.
Deeks, Steven G.
Li, Jonathan Z.
Ongoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory Agents
title Ongoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory Agents
title_full Ongoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory Agents
title_fullStr Ongoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory Agents
title_full_unstemmed Ongoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory Agents
title_short Ongoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory Agents
title_sort ongoing clinical trials of human immunodeficiency virus latency-reversing and immunomodulatory agents
topic Review Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5066458/
https://www.ncbi.nlm.nih.gov/pubmed/27757411
http://dx.doi.org/10.1093/ofid/ofw189
work_keys_str_mv AT delagreverieheloisem ongoingclinicaltrialsofhumanimmunodeficiencyviruslatencyreversingandimmunomodulatoryagents
AT delaugerreconstance ongoingclinicaltrialsofhumanimmunodeficiencyviruslatencyreversingandimmunomodulatoryagents
AT lewinsharonr ongoingclinicaltrialsofhumanimmunodeficiencyviruslatencyreversingandimmunomodulatoryagents
AT deekssteveng ongoingclinicaltrialsofhumanimmunodeficiencyviruslatencyreversingandimmunomodulatoryagents
AT lijonathanz ongoingclinicaltrialsofhumanimmunodeficiencyviruslatencyreversingandimmunomodulatoryagents